CPH vs. CRON, THCX, DHT.UN, WEED, GUD, ACB, OGI, SUGR, FIRE, and EPI
Should you be buying Cipher Pharmaceuticals stock or one of its competitors? The main competitors of Cipher Pharmaceuticals include Cronos Group (CRON), Hydropothecary (THCX), DRI Healthcare Trust (DHT.UN), Canopy Growth (WEED), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Organigram (OGI), SugarBud Craft Growers (SUGR), Supreme Cannabis (FIRE), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Cipher Pharmaceuticals vs. Its Competitors
Cipher Pharmaceuticals (TSE:CPH) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
Cipher Pharmaceuticals currently has a consensus target price of C$14.75, suggesting a potential downside of 2.19%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Cipher Pharmaceuticals is more favorable than Cronos Group.
In the previous week, Cronos Group's average media sentiment score of 0.67 beat Cipher Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.
Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
Cipher Pharmaceuticals has a net margin of 59.92% compared to Cronos Group's net margin of -42.65%. Cipher Pharmaceuticals' return on equity of 17.93% beat Cronos Group's return on equity.
3.2% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Cronos Group shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cipher Pharmaceuticals has a beta of 0.774739, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.299122, meaning that its share price is 30% more volatile than the S&P 500.
Summary
Cipher Pharmaceuticals and Cronos Group tied by winning 7 of the 14 factors compared between the two stocks.
Get Cipher Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cipher Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:CPH) was last updated on 10/8/2025 by MarketBeat.com Staff
